INTRODUCTION
Paget's disease is subdivided into mammary Paget's disease (MPD) and extramammary Paget's disease (EMPD). Over 95% of MPDs are associated with an underlying in-situ or invasive ductal carcinoma of the breast, whereas the remaining five percent are believed to arise from Toker cells of the skin or from pluripotent stem cells [1] [2] [3] [4] [5] .
EMPD was first described by Crocker in 1889 in a patient with urinary bladder carcinoma who presented an eczematous lesion of the scrotum and penis 6 . EMPD is mainly observed in skin regions that are rich in apocrine and apo-eccrine glands 7 and thus most commonly affects the external female ano-genital region 8 as well as the axilla, umbilicus, eyelids and external ear channel [9] [10] [11] . Cells in the so-called mammary-like glands (MLGs) 12-13 of the ano-genital region, or in the skin adherence glands, Toker cells of the epidermis, pluripotent stem cells 4, [14] [15] and infiltrating urothelial carcinomas with involvement of the epidermis 8 have been discussed as histogenetic origins of EMPD.
NY-BR-1 is a recently isolated differentiation antigen 16 . The NY-BR-1 protein is expressed in normal and in neoplastic breast epithelium, skin andexal tumors [17] [18] and in MLGs of the ano-genital region 19 . The NY-BR-1 gene was identified by SEREX analysis (Serological Analysis of Recombinant Expression libraries) of a patient with metastatic breast carcinoma. The NY-BR-1 gene is located on chromosome 10p11-p12
and is composed of 37 exons. It encodes a peptide of MW 150,000-160,000, a putative transcription factor 20 . As an official Hugo name, NY-BR-1 has been designated as ANKRD30A. Although NY-BR-1 mRNA could be detected in different organs such as testis or the prostate, its protein expression is restricted to normal and neoplastic breast epithelium and adnexal tumors of the skin 18, 21 . NY-BR-1 is therefore classified as a differentiation antigen of the mammary gland. Our recent immunohistochemical studies have shown that NY-BR-1 is expressed in about 60%
of breast cancers [17] [18] 21 . Due to its organ-specificity, NY-BR-1 can potentially be used for diagnostic purposes in surgical pathology. NY-BR-1 protein expression has not been studied yet in Paget's disease.
Here Gallen, Switzerland. The patients' ages ranged from 44 to 89 years (median 73 years).
There were 22 female and 4 male patients. Twenty-one EMPDs were located in the vulva, one was paravulvar, one orginated from the perianal region (male patient), two from the anal region (both male patients) and one from the preputium.
In six patients, tissue from recurrent EMPD was available in follow-up biopsies (between 2 and 24 years after first diagnosis). In all patients with EMPD no regional invasive carcinoma was known at the time of primary EMPD manifestation or during follow-up.
Control cases
A tissue micro-array with 382 endometrial cancers was analyzed for the presence of NY-BR-1 expression as an additional marker in the differential diagnosis of EMPD.
12 cases of in situ squamous carcinoma of the skin (Bowen's disease) were also selected and examined on whole tissue sections. Selection criteria for Bowen disease included diagnostic morphological features for in situ carcinoma of the skin without evidence of glandular cells within the epidermis. 
Histology
The surgical specimens were fixed in 4% buffered formalin and submitted for histology. All MPD and EMPD diagnoses as well as the control cases were evaluated by two independent pathologists (OG & ZV). 3-4-micrometer sections from the paraffin-embedded tissue were taken for immunohistochemistry. All cases were routine stained by hematoxylin and eosin (H&E).
Immunohistochemistry and fluorescence in situ hybridization (FISH)
Immunohistochemistry was performed with the Ventana Benchmark automated staining system using Ventana reagents for the entire procedure. Primary antibodies were detected using the iVIEW DAB detection kit and the signal was enhanced using the amplification kit. AG Diagnostic Division, Baar, Switzerland) and an Olympus microscope, as previously described 17 . Her2 status and copy number analysis was carried out according to the current ASCO guidelines 22 . were not considered.
RESULTS

NY-BR-1 expression in mammary Paget's disease
Eighteen of 24 MPDs (75 %) showed NY-BR-1 expression (Table 1) . NY-BR-1 immunoreactivity scores in MPD were always identical to the immunoreactivity score in the underlying DCIS. However, in 3 of 15 MPDs (20%) with synchronous invasive breast cancer, a lower NY-BR-1 score was observed in the invasive carcinoma.
NY-BR-1 expression in extra-mammary Paget's disease
Twenty-one of 26 EMPD cases (80.8%) demonstrated NY-BR-1 expression (Table 2) as (Table 2 ). (Table 3) .
Axillary apo-eccrine glands
18 out of 48 eccrine glands of the axillary regions were positive for NY-BR-1 (37%). In situ skin squamous cell carcinomas 12 skin samples with in situ squamous cell carcinoma were negative for NY-BR-1.
Tissue micro array with endometrial carcinoma samples (n=382).
All 382 spots with endometrium carcinomas were negative for NY-BR-1.
NY-BR-1 immunoreactivity was observed in all cases as a nuclear and/or cytoplasmic reaction product.
NY-BR-1 immunohistochemistry as a diagnostic marker
The 
DISCUSSION
In our analysis, a recently developed NY-BR-1-specific monoclonal antibody directed against an NY-BR-1 epitope between amino acid residues 851 to 921, corresponding to exons 27 to 30 of the NY-BR-1 gene was used. With this antibody, we have previously demonstrated in cell lines as well as in formalin-fixed and paraffinembedded tissue that NY-BR-1 is primarily a breast epithelium differentiation antigen, which is expressed in normal and neoplastic breast epithelium and in adnexal tumors of the skin. A specific, predominantly cytoplasmic staining combined with nuclear staining was shown by confocal microscopy 17 . This staining property could be achieved at a dilution of 1: 400, which resulted in signals only in cells of the ductulo-lobular units and in breast cancer cells 17, 21 . Our previous study on more than
breast carcinoma lesions has shown that NY-BR-1 expression is associated with tumor differentiation, HER2/neu-gene-, EGFR-and ER-status of breast cancer as well
as with prognosis 21 . It was also shown that NY-BR-1 expression is regulated by the estrogen receptor alpha 18 .
Based on these observations, we set out to study NY-BR-1 expression in mammaryand extramammary Paget's disease. The present study shows for the first time that both EMPD and MPD are frequently NY-BR-1 positive. Compared to the results of our previous analyses 17, 21 , the prevalence of NY-BR-1 expression in MPD and EMPD (75-80%) is similar to that of DCIS (79%) but higher than in invasive breast cancer (61% The differential diagnosis of MPD and EMPD includes superficial spreading variants of malignant melanoma in situ (MMIS) and pagetoid Bowen disease (PBD). S100 and HMB45 are specific and sensitive markers in distinguishing EMPD from MMIS 28 .
Lack of NY-BR-1 expression on the RNA and protein level has previously been shown in malignant melanoma 17, 29 . When distinguishing MPD and EMPD from PBD, the antibodies CK7, CK20, CEA and GCDFP15 are frequently utilized 30-33 .
CK7 is highly sensitive for MPD as well as for EMPD, but it can also be positive in some cases of PBD. GCDFP-15 and CEA are more specific since they are clearly negative in squamous cell lesions 34 . NY-BR-1 is slightly less sensitive than CEA or GCDFP-15, but in one of our patients CEA and GCDFP-15 were negative, while NY- As to the histogenesis of EMPD and related cells (Toker cells, mammary-like glands or apo-eccrine glands of the axilla), the differential expression of proteins other than NY-BR-1 is also of interest 15 . There is some heterogeneity in the expression profile of these lesions: EMPDs for example can exhibit both ecto-or endodermal phenotype, resulting in being positive or negative for GCDFP-15 and CK20, which however does not influence the constant CK7 expression 35 . Toker cells on the other hand consequently express CK7 and hormone receptors, can be positive for MUC1, but practically never express CEA, EMA S100, GCDFP15 or cytokeratin 20, similar to our experience in this study [14] [15] 36 . Mammary-like glands can exhibit a phenotype similar to that of the breast parenchyma, they are often hormone receptor and GCDFP-15 positive and as we could also demonstrate in this study, they can show an expression of the breast differentiation antigen, NY-BR-1 as well [37] [38] . Apoeccrine glands of the axilla have been shown to have similarity to breast phenotype, as being positive for GCDFP-15, CEA and S100 7 . Interestingly, NY-BR-1 positivity in our study was found in a higher frequency among apocrine than in eccrine cell types in the axillary glands, providing further evidence for a histogenetical link between axillary glands and breast specific glands. 
